PortalPublikationenPrognostic Value of Bioactive Adrenomedullin in Critically I...

Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study

Standard

Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study. / Simon, Tim-Philipp; Stoppe, Christian; Breuer, Thomas; Stiehler, Lara; Dreher, Michael; Kersten, Alexander; Kluge, Stefan; Karakas, Mahir; Zechendorf, Elisabeth; Marx, Gernot; Martin, Lukas.

in: J CLIN MED, Jahrgang 10, Nr. 8, 1667, 13.04.2021.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Simon, T-P, Stoppe, C, Breuer, T, Stiehler, L, Dreher, M, Kersten, A, Kluge, S, Karakas, M, Zechendorf, E, Marx, G & Martin, L 2021, 'Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study', J CLIN MED, Jg. 10, Nr. 8, 1667. https://doi.org/10.3390/jcm10081667

APA

Simon, T-P., Stoppe, C., Breuer, T., Stiehler, L., Dreher, M., Kersten, A., Kluge, S., Karakas, M., Zechendorf, E., Marx, G., & Martin, L. (2021). Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study. J CLIN MED, 10(8), [1667]. https://doi.org/10.3390/jcm10081667

Vancouver

Simon T-P, Stoppe C, Breuer T, Stiehler L, Dreher M, Kersten A et al. Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study. J CLIN MED. 2021 Apr 13;10(8). 1667. https://doi.org/10.3390/jcm10081667

Bibtex

@article{5a8e417adb644b0fa0fe0c784ea4119e,
title = "Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study",
abstract = "The coronavirus disease 2019 (COVID-19) pandemic has placed a significant burden on hospitals worldwide. Objective biomarkers for early risk stratification and clinical management are still lacking. The aim of this work was to determine whether bioactive adrenomedullin can assist in the risk stratification and clinical management of critically ill COVID-19 patients. Fifty-three patients with confirmed COVID-19 were included in this prospective observational cohort study between March and April 2020. Bioactive adrenomedullin (bio-ADM) plasma concentration was measured daily for seven days after admission. The prognostic value and clinical significance of bio-ADM plasma levels were evaluated for the severity of respiratory failure, the need for extracorporeal organ support and outcome (28-day mortality). Bio-ADM levels increased with the severity of acute respiratory distress syndrome (ARDS; p < 0.001) and were significantly elevated in invasively ventilated patients (p = 0.006) and patients in need of extracorporeal membrane oxygenation (p = 0.040) or renal replacement therapy (RRT; p < 0.001) compared to patients without these conditions. Non-survivors showed significantly higher bio-ADM levels than survivors (p = 0.010). Bio-ADM levels predicted 28-day mortality (C-index 0.72, 95% confidence interval 0.56-0.87, p < 0.001). Bio-ADM plasma levels correlate with disease severity, the need for extracorporeal organ assistance, and outcome, and highlight the promising value of bio-ADM in the early risk stratification and management of patients with COVID-19.",
author = "Tim-Philipp Simon and Christian Stoppe and Thomas Breuer and Lara Stiehler and Michael Dreher and Alexander Kersten and Stefan Kluge and Mahir Karakas and Elisabeth Zechendorf and Gernot Marx and Lukas Martin",
year = "2021",
month = apr,
day = "13",
doi = "10.3390/jcm10081667",
language = "English",
volume = "10",
journal = "J CLIN MED",
issn = "2077-0383",
publisher = "MDPI AG",
number = "8",

}

RIS

TY - JOUR

T1 - Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study

AU - Simon, Tim-Philipp

AU - Stoppe, Christian

AU - Breuer, Thomas

AU - Stiehler, Lara

AU - Dreher, Michael

AU - Kersten, Alexander

AU - Kluge, Stefan

AU - Karakas, Mahir

AU - Zechendorf, Elisabeth

AU - Marx, Gernot

AU - Martin, Lukas

PY - 2021/4/13

Y1 - 2021/4/13

N2 - The coronavirus disease 2019 (COVID-19) pandemic has placed a significant burden on hospitals worldwide. Objective biomarkers for early risk stratification and clinical management are still lacking. The aim of this work was to determine whether bioactive adrenomedullin can assist in the risk stratification and clinical management of critically ill COVID-19 patients. Fifty-three patients with confirmed COVID-19 were included in this prospective observational cohort study between March and April 2020. Bioactive adrenomedullin (bio-ADM) plasma concentration was measured daily for seven days after admission. The prognostic value and clinical significance of bio-ADM plasma levels were evaluated for the severity of respiratory failure, the need for extracorporeal organ support and outcome (28-day mortality). Bio-ADM levels increased with the severity of acute respiratory distress syndrome (ARDS; p < 0.001) and were significantly elevated in invasively ventilated patients (p = 0.006) and patients in need of extracorporeal membrane oxygenation (p = 0.040) or renal replacement therapy (RRT; p < 0.001) compared to patients without these conditions. Non-survivors showed significantly higher bio-ADM levels than survivors (p = 0.010). Bio-ADM levels predicted 28-day mortality (C-index 0.72, 95% confidence interval 0.56-0.87, p < 0.001). Bio-ADM plasma levels correlate with disease severity, the need for extracorporeal organ assistance, and outcome, and highlight the promising value of bio-ADM in the early risk stratification and management of patients with COVID-19.

AB - The coronavirus disease 2019 (COVID-19) pandemic has placed a significant burden on hospitals worldwide. Objective biomarkers for early risk stratification and clinical management are still lacking. The aim of this work was to determine whether bioactive adrenomedullin can assist in the risk stratification and clinical management of critically ill COVID-19 patients. Fifty-three patients with confirmed COVID-19 were included in this prospective observational cohort study between March and April 2020. Bioactive adrenomedullin (bio-ADM) plasma concentration was measured daily for seven days after admission. The prognostic value and clinical significance of bio-ADM plasma levels were evaluated for the severity of respiratory failure, the need for extracorporeal organ support and outcome (28-day mortality). Bio-ADM levels increased with the severity of acute respiratory distress syndrome (ARDS; p < 0.001) and were significantly elevated in invasively ventilated patients (p = 0.006) and patients in need of extracorporeal membrane oxygenation (p = 0.040) or renal replacement therapy (RRT; p < 0.001) compared to patients without these conditions. Non-survivors showed significantly higher bio-ADM levels than survivors (p = 0.010). Bio-ADM levels predicted 28-day mortality (C-index 0.72, 95% confidence interval 0.56-0.87, p < 0.001). Bio-ADM plasma levels correlate with disease severity, the need for extracorporeal organ assistance, and outcome, and highlight the promising value of bio-ADM in the early risk stratification and management of patients with COVID-19.

U2 - 10.3390/jcm10081667

DO - 10.3390/jcm10081667

M3 - SCORING: Journal article

C2 - 33924637

VL - 10

JO - J CLIN MED

JF - J CLIN MED

SN - 2077-0383

IS - 8

M1 - 1667

ER -